News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Varian Medical Systems (VAR) Touts U.S., U.K. Wins for Brachytherapy Treatment, Profits Up 6 Pct in Q1



1/29/2013 9:00:48 AM

Palo Alto, Calif.-based medical device company Varian gets twin regulatory wins for its brachytherapy treatment for prostate cancer and posts stronger earnings in Q1. Varian Medical Systems (NYSE:VAR) is touting a pair of regulatory wins for the next generation of its Vitesse brachytherapy treatment for prostate cancer. Palo Alto, Calif.-based Varian received 510(k) clearance from the FDA and CE Mark approval in the European Union for the latest version of Vitesse, which company officials said reduces the complexity and number of steps involved in planning and completing brachytherapy treatment for prostate cancer. Brachytherapy involves delivering radiotherapy from inside the body by placing a tiny radioactive source directly into the tumor.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES